3,9-disubstituted-spiro(5.5)undecanes active on the cardiovascular system, process for their preparation and pharmaceutical composition containing same

3,9-disubstituted-spiro[5.5]undecanes of formula (I):

• ##STR7## wherein:
• R represents:
• hydrogen or
• a C.sub.2 -C.sub.6 alkyl or C.sub.2 -C.sub.6 alkenyl group unsubstituted or substituted independently by a quaternary ammonium group or one or more hydroxy, C.sub.1 -C.sub.6 alkoxy, carboxy, NR.sup.4 R.sup.5, NHC(NH)NHR.sup.6 or C(NH)NR.sup.7 R.sup.8 groups,
• wherein NR.sup.4 R.sup.5 represents amino, methylamino, ethylamino, propylamino, isopropylamino, allylamino, propargylamino, dimethylamino, pyrrolidinyl, morpholino, piperazinyl, 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-phenylpiperazinyl, 1-imidazolyl, guanidino, 2-aminoethylamino, 3-aminopropylamino, 2-(1-pyrrolidinyl)ethylamion, 3(1-pyrrolidinyl)propylamino, 3-amino-2-hydroxypropylamino, 3-(1-pyrrolidinyl)-2-hydroxypropylamino or 2,3-diaminopropylamino
• R.sup.6, R.sup.7 and R.sup.8, which are the same or different, are H or C.sub.1 -C.sub.4 lower alkyl;
• n is an integer from 0 to 4;
• and
• Y is oxygen or sulphur;
• the symbol - - - means single or double bond with the proviso that
• (i) when - - - is a single bond
• A represents a C--H or C--OR.sup.1 group wherein R.sup.1 is H or CH.sub.3 and
• B represents:
• a C.sub.1 -C.sub.6 lower alkyl or C.sub.2 -C.sub.6 alkenyl chain substituted by hydroxy, amino, oxo, .dbd.N--NR.sup.2 --C(.dbd.Z)NHR.sup.3 ;
• or a saturated or unsaturated mono-heterocyclic ring,
• wherein .dbd.N--NR.sup.2 --C(.dbd.Z)NHR.sup.3 is guanidinoimino, ureidoimino, thioureidoimino, N-methylguanidimino, N,N'-dimethylguanidinoimino, (2-imidazolin-2-yl)hydrazono or 2-(2-imidazolyl)hydrazono, and,
• the saturated or unsaturated mono-heterocyclic ring is isoxyranyl, 2-aziridinyl, 2-furyl, 2-thienyl, 2-imidazolyl, 2-pirrolyl, 2-tetrahydrofuryl, 3-furyl, 3-thienyl, 4-imidazolyl, 3-pirrolyl, 3-tetrahydrofuryl, 2-oxo-(5H)-3-furyl, 2-oxo-(5H)-4-furyl, 2-thiazolyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 2-pyridinyl-N-oxide, 3-pyridinyl-N-oxide, 2-oxo-(1H)-4-pyridinyl, 2-oxo-(1H)-5-pyridinyl or 2-oxo-(2H)-5-pyranyl, and
• (ii) when - - - is a double bond
• A represents a carbon atom C and
• B represents:
• a .dbd.N--NR.sup.2 --C(.dbd.Z)NHR.sup.3 group as above-identified;
• and the pharmaceutically acceptable salts as well as the optical antipodes, i.e. the enantiomers, the racemic mixture of the optical antipodes, or other mixtures thereof, the geometric isomers and their mixtures, the diastereoisomers and mixtures of diastereoisomers of the compounds of formula (I).